Feature|Articles|November 18, 2026

Weighing Cross-Trial Data and Patient Timelines in Alopecia Areata Treatment

Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Jessica Mercer, MD, debated severity scoring, trial data, and monitoring when selecting JAK inhibitors for alopecia areata.

Jessica Mercer, MD, dermatologist, co-managing partner, and director of dermatopathology at Georgia Dermatology Partners, recently moderated a Dermatology Times Case-Based Roundtable event in Atlanta, Georgia. The program, titled “Alopecia Areata in Practice: Individualizing Care Through Patient Cases,” brought together dermatologists, nurse practitioners, and physician assistants. Attendees worked through 3 cases and reviewed the 3 FDA-approved JAK inhibitors for severe disease: deuruxolitinib (Leqselvi; Sun Pharmaceutical Industries), ritlecitinib (Litfulo; Pfizer), and baricitinib (Olumiant; Eli Lilly).¹

Defining Severity and Setting Expectations for Time-Sensitive Treatment Goals

The first case involved a 33-year-old man with 45% scalp hair loss, minimal response to 4 months of topical corticosteroid, and a wedding in 6 months. In a poll, 47% of attendees named extent of scalp involvement as the top trigger for systemic escalation, and 41% named psychosocial or quality of life impact. Mercer favors the Alopecia Areata Scale over the Severity of Alopecia Tool (SALT) alone, because secondary criteria such as eyebrow or eyelash involvement and rapid progression can move a patient into a higher severity category.²

Attendees favored a cautiously optimistic message on timing, paired with a backup plan such as camouflage. “Underpromise and overdeliver,” an attendee said. Of polled attendees, 69% called speed of response extremely influential in treatment selection.

In pooled THRIVE-AA1 and THRIVE-AA2 data, 31.0% of patients on deuruxolitinib reached a SALT score of 20 or less at week 24, compared with 0.8% on placebo.3,4 In BRAVE-AA1, 22% of patients on baricitinib 2 mg and 38.8% on 4 mg reached the same threshold at week 36.⁵ Mercer cautioned against comparing numbers across trials, citing differences in end points, enrolled populations, and permitted adjunctive therapy.

“Looking at the exclusion criteria has been massive,” an attendee said. Some attendees reported mixed results with deuruxolitinib in adults, and others described baricitinib as slow. “It’s a slow burn,” an attendee said.

Payer requirements to start baricitinib at 2 mg drew criticism for patients with a defined timeline. “Why am I going to waste one of those months on a lower-dose medication?” an attendee said.

Patient-Reported Outcomes in Rapidly Progressing Disease

The second case featured a 29-year-old woman whose scalp hair loss rose from 21% to 36% in 3 months, with significant anxiety and no eyebrow or eyelash involvement. Attendees classified her as moderate by objective criteria, though one noted a possible ophiasis pattern. All supported systemic therapy.

Mercer reviewed patient-reported outcomes, including Skindex-16 and Hospital Anxiety and Depression Scale (HADS) scores. Skindex-16 scores fell from 57.1 to 30 at 48 weeks in an observational study of baricitinib⁶ and from 48.4 to 30.9 at 24 weeks in one of ritlecitinib.⁷

“These medications, they are not just growth stimulants; they’re antidepressants,” Mercer said. One attendee asks patients to show their hairstylist photos at each visit. “Hairstylists also double as therapists too,” the attendee said.

Mercer waits about 6 months before judging response, based on trial durations. In a poll, 75% of attendees would switch to another JAK inhibitor after an inadequate response.

Mercer said she would first add an adjunct such as oral minoxidil. “We have a wallet of options, not a bag of options,” Mercer said.

Baseline Workup and Long-Term Monitoring

The third case involved a 42-year-old man with 85% scalp hair loss and new eyebrow and beard involvement. His CYP2C9 genotype indicated a normal metabolizer, and baseline CBC, hepatitis screening, and TB screening were unremarkable. In a poll, 69% of attendees said the CYP2C9 result only rules a patient in or out for deuruxolitinib.

Mercer explains the test to patients as a glimpse into side effect risk. One attendee reported a 3-week turnaround, and attendees described lack of an in-office lab as a barrier.

Mercer once checked labs at baseline and at 1, 3, and 6 months, but now checks at baseline and 6 months, with earlier testing for older patients. Attendees also discussed zoster vaccination for adults starting a JAK inhibitor.

Mercer noted deuruxolitinib safety data covered 24 weeks, while ritlecitinib and baricitinib data extend to 3 years.8,9 She frames boxed warning discussions by screening for personal and family history first. “So you want to explain, not excuse,” Mercer said.

In the first year, Mercer sees patients at 3 and 6 months, then about every 6 months while disease is stable.

In a final poll, 12 of 33 selections indicated attendees already felt comfortable with JAK inhibitors. Practical guidance on testing and patient selection and best practices for monitoring each drew 6 selections.

References

  1. FDA-approved JAK inhibitors. National Alopecia Areata Foundation. Accessed November 2, 2026. https://www.naaf.org/navigation-toolkit/fda-approved-jak-inhibitors/
  2. King BA, Senna MM, Ohyama M, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022;12(4):825-834. doi:10.1007/s13555-022-00711-3
  3. King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880-888. doi:10.1016/j.jaad.2024.06.097
  4. Tsianakas A, Passeron T, Magnolo N, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2026;94(4):1134-1143. doi:10.1016/j.jaad.2025.11.070
  5. King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687-1699. doi:10.1056/NEJMoa2110343
  6. Piraccini BM, Cedirian S, Pampaloni F, et al. Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results. J Eur Acad Dermatol Venereol. 2026;40(2):224-231. doi:10.1111/jdv.70067
  7. Starace M, Rapparini L, Pampaloni F, et al. Ritlecitinib for severe alopecia areata: a 24-week, multicentre, real-world study. Am J Clin Dermatol. 2026;27(3):621-630. doi:10.1007/s40257-026-01022-5
  8. Senna M, Soung J, Figueras I, et al. Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: 3-year results from the ALLEGRO phase 2b/3 and ALLEGRO-LT phase 3 clinical studies. Am J Clin Dermatol. 2026;27(5):1091-1105. doi:10.1007/s40257-026-01029-y
  9. Senna M, Mostaghimi A, Sinclair R, et al. Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2. J Am Acad Dermatol. 2026;94(4):1126-1133. doi:10.1016/j.jaad.2025.11.064

Related to this article

TanPrevent and the Case for Preventing Thousands of Melanomas
Learn why indoor tanning remains a preventable source of melanoma, what research suggests about why some patients experience difficulty stopping, and how a clinical pilot called TanPrevent could connect education with follow-up support to help them quit and stay quit.